1q21.1 microdeletion syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:250989OMIM:612474Q93.5
Who is this for?
Show terms as
2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

1q21.1 microdeletion syndrome (also known as 1q21.1 deletion syndrome or chromosome 1q21.1 deletion syndrome) is a rare genetic condition caused by a small deletion of genetic material on the long arm of chromosome 1 at position q21.1. This region contains several genes that play important roles in growth and neurodevelopment. The deletion typically spans approximately 1.35 megabases and can occur de novo (as a new event) or be inherited from a parent who may be mildly affected or apparently unaffected, reflecting the variable expressivity and incomplete penetrance characteristic of this condition. The syndrome affects multiple body systems, most notably the neurological, musculoskeletal, and cardiovascular systems. Key clinical features include mild to moderate intellectual disability, developmental delay (particularly speech and language delay), microcephaly (abnormally small head), short stature, and distinctive but subtle facial features. Congenital heart defects, including patent ductus arteriosus and septal defects, are reported in some individuals. Eye abnormalities such as cataracts have also been described. Psychiatric and behavioral features are common and may include autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), and schizophrenia or other psychiatric conditions in adulthood. The clinical presentation is highly variable, even among affected members of the same family, and some carriers may have no apparent symptoms. There is currently no cure or specific targeted therapy for 1q21.1 microdeletion syndrome. Management is supportive and symptom-based, involving early intervention programs, speech and occupational therapy, special education services, and behavioral support. Cardiac anomalies may require surgical or medical intervention. Regular developmental and neuropsychiatric monitoring is recommended. Genetic counseling is important for affected individuals and their families to understand recurrence risks and the variable nature of the condition.

Also known as:

Clinical phenotype terms— hover any for plain English:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for 1q21.1 microdeletion syndrome.

View clinical trials →

No actively recruiting trials found for 1q21.1 microdeletion syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the 1q21.1 microdeletion syndrome community →

Specialists

2 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to 1q21.1 microdeletion syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open 1q21.1 microdeletion syndromeForum →

No community posts yet. Be the first to share your experience with 1q21.1 microdeletion syndrome.

Start the conversation →

Latest news about 1q21.1 microdeletion syndrome

No recent news articles for 1q21.1 microdeletion syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about 1q21.1 microdeletion syndrome

What is 1q21.1 microdeletion syndrome?

1q21.1 microdeletion syndrome (also known as 1q21.1 deletion syndrome or chromosome 1q21.1 deletion syndrome) is a rare genetic condition caused by a small deletion of genetic material on the long arm of chromosome 1 at position q21.1. This region contains several genes that play important roles in growth and neurodevelopment. The deletion typically spans approximately 1.35 megabases and can occur de novo (as a new event) or be inherited from a parent who may be mildly affected or apparently unaffected, reflecting the variable expressivity and incomplete penetrance characteristic of this condi

How is 1q21.1 microdeletion syndrome inherited?

1q21.1 microdeletion syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Which specialists treat 1q21.1 microdeletion syndrome?

2 specialists and care centers treating 1q21.1 microdeletion syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.